Precigen (PGEN) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Precigen (PGEN) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 144.8% versus a loss of 11.1%. Over five years, PGEN leads with a +68.0% price change compared with +9.3% for VRDN. Precigen is the larger company by market cap ($2.80 billion vs $2.11 billion), about 1.3 times the size, while Viridian Therapeutics is growing revenue faster (+23359.9% vs +146.7%).
Viridian Therapeutics converts more of its revenue into profit, with a net margin of -483.6% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGEN | VRDN |
|---|---|---|
| Share price | $7.81 | $18.66 |
| Market cap | $2.80B | $2.11B |
| 1-day change | +2.76% | +1.74% |
| YTD return | +86.84% | -40.04% |
| 1-year return | +144.83% | -11.10% |
| 5-year return | +67.96% | +9.31% |
| EPS (TTM) | $-1.04 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.68M | $70.85M |
| Revenue growth (YoY) | +146.73% | +23359.93% |
| Net income (latest FY) | $-250.64M | $-342.60M |
| Operating margin | -1141.13% | -512.91% |
| Net margin | -2588.21% | -483.57% |
| 52-week high | $8.98 | $34.29 |
| 52-week low | $3.04 | $13.18 |
| Distance from 52-week high | -13.03% | -45.58% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +74.78% | +96.95% |
| Average volume | 5.03M | 1.71M |
| Shares outstanding | 358.04M | 113.29M |
| Employees | 160 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed VRDN by 155.9 percentage points over the past year.
- Viridian Therapeutics is more profitable, keeping -483.6 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +146.73%).
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
PGEN vs VRDN FAQ
Which is bigger, Precigen or Viridian Therapeutics?
Precigen (PGEN) is larger, with a market capitalization of $2.80B compared with $2.11B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, PGEN or VRDN?
PGEN returned +144.83% over the past 12 months, compared with -11.10% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Precigen and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.